An interventional study of i-Lumen AMD in Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD) and Intermediate AMD, sponsored by i-Lumen Scientific AUS PTY LTD. Recruiting at 13 sites in 4 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by i-Lumen Scientific AUS PTY LTD · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to characterize the safety and effectiveness of the i-Lumen AMD transpalpebral microcurrent device and therapy in patients with intermediate to advanced nonexudative AMD.
Participants will:
1,474 studies on the registry are indexed under Macular Degeneration; 206 are open to participants now.
This study's planned enrollment of 100 is above the median of 51 across 985 interventional studies indexed under Macular Degeneration.
Browse Macular Degeneration studies →This is the only study on the registry with i-Lumen Scientific AUS PTY LTD as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Active transpalpebral microcurrent therapy
Device: i-Lumen AMD
Sham transpalpebral microcurrent therapy
Device: i-Lumen AMD
i-Lumen AMD transpalpebral microcurrent stimulation system
Mean Change BCVA from Baseline
Mean change in per-eye (treated study eye \[unilateral\] or treated primary study eye \[bilateral\]) from Baseline in distance BCVA letter score on the ETDRS VA chart, active vs sham.
Time frame: Month 3
Portion of per-eye Responders
1\. Difference in proportion of per-eye (treated study eye \[unilateral\] or treated primary study eye \[bilateral\]) gaining ≥10 letters from Baseline in distance BCVA ETDRS, active vs sham.
Time frame: Month 3
Mean Change BCVA from Baseline
Mean change in per-eye (treated study eye \[unilateral\] or treated primary study eye \[bilateral\]) from Baseline in distance BCVA letter score on the ETDRS VA chart, active vs sham.
Time frame: Month 6
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.